Akebia Therapeutics' Series C Round

Akebia Therapeutics raised a round of funding on June 04, 2013.

Akebia Therapeutics is focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia's lead product candidate, vadadustat, is an inv…

Articles about Akebia Therapeutics' Series C Round: